Literature DB >> 10869774

European sero-epidemiology network: standardisation of the results of diphtheria antitoxin assays.

C von Hunolstein1, H Aggerbeck, N Andrews, G Berbers, F Fievet-Groyne, P A Maple, R M Olander, M Raux, A Tischer.   

Abstract

A European Sero-Epidemiological Network (ESEN) was established with the aim to co-ordinate and harmonise serological surveillance of immunity to communicable diseases in Europe. In this study the inter-laboratory standardisation of diphtheria toxin antibody measurements is reported. A standard panel of 162 sera was tested by the participating laboratories using an in vitro assay of their choice: VERO cell toxin neutralisation assay (NT), double-antigen delayed time-resolved fluorescence immuno-assay (DA-DELFIA), double-antigen enzyme-linked immunosorbent assay (DAE), toxin binding inhibition test (ToBI) and an indirect enzyme-linked immunosorbent assay (ELISA). The results were standardised using regression against the NT. The variations due to inter-laboratory and inter-assay variation, which would otherwise make it difficult directly to compare the main serum bank results by the different laboratories and the various assays were successfully minimised by the standardisation. The regression equations obtained will be used to transform the respective local results of testing the main serum bank into the reference test unitages. This study also gave the opportunity to compare the various assays within and between laboratories. This demonstrated a very high correlation between DA-DELFIA, DAE, ToBI and the NT. The ELISA showed a good correlation, too, however sera below some 0.1 IU/ml were overestimated.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10869774     DOI: 10.1016/s0264-410x(00)00125-0

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  7 in total

1.  External quality assessment for the determination of diphtheria antitoxin in human serum.

Authors:  Paolo Di Giovine; Antonella Pinto; Rose-Marie Olander; Dorothea Sesardic; Paul Stickings; Guy Berbers; Shona Neal; Androulla Efstratiou; Ruta Paberza; Snieguole Dauksiene; Marina Bujko; Antoaneta Detcheva; Unna Joks; Belkis Levent; Christina von Hunolstein
Journal:  Clin Vaccine Immunol       Date:  2010-07-07

2.  Lot-to-lot consistency study of the fully liquid pentavalent DTwP-HepB-Hib vaccine Quinvaxem (®) demonstrating clinical equivalence, suitability of the vaccine as a booster and concomitant administration with measles vaccine.

Authors:  Sanet Aspinall; Deirdre Traynor; Philip Bedford; Katharina Hartmann
Journal:  Hum Vaccin Immunother       Date:  2012-08-01       Impact factor: 3.452

3.  Performance of a time-resolved fluorescence immunoassay for measuring varicella-zoster virus immunoglobulin G levels in adults and comparison with commercial enzyme immunoassays and Merck glycoprotein enzyme immunoassay.

Authors:  P A C Maple; J Gray; J Breuer; G Kafatos; S Parker; D Brown
Journal:  Clin Vaccine Immunol       Date:  2006-02

4.  A phase III single arm, multicenter, open-label study to assess the immunogenicity and tolerability of a pentavalent DTwP-HepB-Hib vaccine in indian infants.

Authors:  Adarsh Eregowda; Sanjay Lalwani; Sukanta Chatterjee; Hoshang Vakil; Khaleel Ahmed; Marco Costantini; Maria Lattanzi
Journal:  Hum Vaccin Immunother       Date:  2013-06-19       Impact factor: 3.452

5.  Comparative seroepidemiology of diphtheria in six European countries and Israel.

Authors:  P di Giovine; G Kafatos; A Nardone; N Andrews; R M Ölander; G Alfarone; K Broughton; D Cohen; B Kriz; I Mikova; D O'Flanagan; F Schneider; I Selga; L Valinsky; I Velicko; I Karacs; R Pebody; C von Hunolstein
Journal:  Epidemiol Infect       Date:  2012-02-24       Impact factor: 4.434

6.  Estimating seroprevalence of vaccine-preventable infections: is it worth standardizing the serological outcomes to adjust for different assays and laboratories?

Authors:  G Kafatos; N Andrews; K J McConway; C Anastassopoulou; C Barbara; F De Ory; K Johansen; J Mossong; K Prosenc; R Vranckx; A Nardone; R Pebody; P Farrington
Journal:  Epidemiol Infect       Date:  2014-11-25       Impact factor: 4.434

7.  A phase I, randomized, controlled, dose-ranging study of investigational acellular pertussis (aP) and reduced tetanus-diphtheria-acellular pertussis (TdaP) booster vaccines in adults.

Authors:  Geert Leroux-Roels; Maria Lattanzi; Claudia Dovali Solis; Mario Contorni; Marco Costantini; Luca Moraschini; Monia Bardelli; Sylvie Bertholet; Erica Borgogni; Francesca Buricchi; Rocco Cantisani; Elisa Faenzi; Oretta Finco; Rosanna Leuzzi; Mariagrazia Pizza; Domenico Rosa; Francesca Schiavetti; Anja Seubert; Fabiana Spensieri; Gianfranco Volpini; Luisanna Zedda; Giuseppe Del Giudice; Ilaria Galgani
Journal:  Hum Vaccin Immunother       Date:  2017-11-27       Impact factor: 3.452

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.